Shifting the lines against central nervous system disorders

« Neurological disorders: a major social challenge and a market in crucial need of therapeutic innovation »

> Mission

Created in 2013, Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's creation stems from the fact that current CNS drugs for neurological disorders - including narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain, psychiatric disorders and epilepsy - have limited efficacy, making the development of new treatments one of the industry's most important challenges.

Former researchers at the French Alternative Energies and Atomic Energy Commission (CEA), founders Franck Mouthon and Mathieu Charvériat were able to identify the significant role that non-neuronal cells (or "glial cells") play in the way in which neurons respond to CNS drugs despite being long neglected by the pharmaceutical industry. Their research led them to discover that they could improve neuron response and thereby increase the efficacy of CNS drugs by modulating the structure of glial cell networks.

This protected technology, which can be applied in the treatment of numerous conditions, involves acting simultaneously on glial cells and neurons. Theranexus is currently developing this unique, breakthrough approach across four pathologies. Within four years, Theranexus has already made significant strides in pre-clinical, clinical and technological developments, including for its first drug candidate, THN102, the demonstration of its superior efficacy and good tolerance in human subjects.

Neurological disorders: a major social challenge and a market in crucial need of therapeutic innovation

Nearly one billion people worldwide suffer from neurological disorders and this number has continued to rise sharply in line with the growing proportion of elderly people in the population. Neurological disorders are one of the leading causes of disability and account for over one-third of health expenses overall (estimated at more than €2,000 billion1,2).

With its innovative platform for generating drug candidates, Theranexus is perfectly positioned to offer solutions to these major medical and industrial needs.

Thanks to its proprietary technology and methods of treatment, Theranexus occupies a unique position to target underserved markets.

1 Source: Gustavsson et al., Eur Neuropsychophamacology, 2011
2 WHO / Neurological Disorders: Public Health Challenges, 2015